FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1520784746> ?p ?o ?g. }

• W1520784746 endingPage "35" @default.
• W1520784746 startingPage "28" @default.
• W1520784746 abstract "What's known on the subject? and What does the study add? Prostate cancer is one of the few solid‐organ cancers in which imaging is not used in the diagnostic process. Novel functional magnetic resonance imaging techniques offer promise but may not be cost‐effective. Prostate HistoScanning ™ (PHS) is an ultrasound‐based tissue characterisation technique that has previously shown encouraging results in the detection of clinically significant prostate cancer. The present study reports on the open ‘unblinded’ phase of a European multicentre study. The prospective ‘blind’ phase is currently in progress and will determine the value of PHS in a robust fashion overcoming many of the biases inherent in evaluating prostate imaging. OBJECTIVE To evaluate the ability of prostate HistoScanning ™ (PHS) an ultrasound (US)‐based tissue characterization application, to detect cancer foci by correlating results with detailed radical prostatectomy (RP) histology. PATIENT AND METHODS In all, 31 patients with organ‐confined prostate cancer, diagnosed on transrectal biopsies taken using US guidance, and scheduled for RP were recruited from six European centres. Before RP three‐dimensional (3D) US raw data for PHS analysis was obtained. Histology by Bostwick Laboratories (London) examined sections obtained from whole mounted glands cut every 3–4 mm. Location and volume estimation of cancer foci by PHS were undertaken using two methods; a manual method and an embedded software tool. In this report we evaluate data obtained from a planned open study phase. The second phase of the study is ‘blinded’, and currently in progress. RESULTS 31 patients were eligible for this phase. Three patients were excluded from analysis due to inadequate scan acquisition and pathology violations of the standard operating procedure. One patient withdrew from the study after 3D TRUS examination. PHS detected cancer ≥0.20 mL in 25/27 prostates (sensitivity 93%). In all, 23 patients had an index focus ≥0.5 mL at pathology, of which 21 were identified as ≥0.5 mL by PHS using the manual method (sensitivity 91%) and 19 were correctly identified as ≥0.5 mL by the embedded tool (sensitivity 83%). In 27 patients, histological analysis found 32 cancerous foci ≥0.2 mL, located in 97 of 162 sextants. After sextant analysis, PHS showed a 90% sensitivity and 72% specificity for the localisation of lesions ≥0.2 mL within a sextant. CONCLUSIONS PHS has the ability to identify and locate prostate cancer and consequently may aid in pre‐treatment and pre‐surgical planning. In men with a lesion identified, it has potential to enable improved targeting, allowing better risk stratification by obtaining more representative cores. However further verification from the results of the blinded phase of this study are awaited." @default.
• W1520784746 created "2016-06-24" @default.
• W1520784746 creator A5006771288 @default.
• W1520784746 creator A5008993286 @default.
• W1520784746 creator A5011942371 @default.
• W1520784746 creator A5021416004 @default.
• W1520784746 creator A5025917996 @default.
• W1520784746 creator A5032851044 @default.
• W1520784746 creator A5036120141 @default.
• W1520784746 creator A5044264142 @default.
• W1520784746 creator A5047328562 @default.
• W1520784746 creator A5066738891 @default.
• W1520784746 creator A5079788588 @default.
• W1520784746 creator A5083172675 @default.
• W1520784746 date "2011-11-17" @default.
• W1520784746 modified "2023-10-18" @default.
• W1520784746 title "Detection, localisation and characterisation of prostate cancer by Prostate HistoScanning™" @default.
• W1520784746 cites W1483897994 @default.
• W1520784746 cites W1974576934 @default.
• W1520784746 cites W1985539036 @default.
• W1520784746 cites W1989952181 @default.
• W1520784746 cites W1990845638 @default.
• W1520784746 cites W1994431559 @default.
• W1520784746 cites W2005711928 @default.
• W1520784746 cites W2014232120 @default.
• W1520784746 cites W2021063134 @default.
• W1520784746 cites W2027142966 @default.
• W1520784746 cites W2032789473 @default.
• W1520784746 cites W2045862330 @default.
• W1520784746 cites W2050752108 @default.
• W1520784746 cites W2061259677 @default.
• W1520784746 cites W2092989749 @default.
• W1520784746 cites W2094118191 @default.
• W1520784746 cites W2128338705 @default.
• W1520784746 cites W2129303461 @default.
• W1520784746 cites W2155530804 @default.
• W1520784746 doi "https://doi.org/10.1111/j.1464-410x.2011.10734.x" @default.
• W1520784746 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22093966" @default.
• W1520784746 hasPublicationYear "2011" @default.
• W1520784746 type Work @default.
• W1520784746 sameAs 1520784746 @default.
• W1520784746 citedByCount "77" @default.
• W1520784746 countsByYear W15207847462012 @default.
• W1520784746 countsByYear W15207847462013 @default.
• W1520784746 countsByYear W15207847462014 @default.
• W1520784746 countsByYear W15207847462015 @default.
• W1520784746 countsByYear W15207847462016 @default.
• W1520784746 countsByYear W15207847462017 @default.
• W1520784746 countsByYear W15207847462018 @default.
• W1520784746 countsByYear W15207847462019 @default.
• W1520784746 countsByYear W15207847462020 @default.
• W1520784746 countsByYear W15207847462021 @default.
• W1520784746 countsByYear W15207847462022 @default.
• W1520784746 countsByYear W15207847462023 @default.
• W1520784746 crossrefType "journal-article" @default.
• W1520784746 hasAuthorship W1520784746A5006771288 @default.
• W1520784746 hasAuthorship W1520784746A5008993286 @default.
• W1520784746 hasAuthorship W1520784746A5011942371 @default.
• W1520784746 hasAuthorship W1520784746A5021416004 @default.
• W1520784746 hasAuthorship W1520784746A5025917996 @default.
• W1520784746 hasAuthorship W1520784746A5032851044 @default.
• W1520784746 hasAuthorship W1520784746A5036120141 @default.
• W1520784746 hasAuthorship W1520784746A5044264142 @default.
• W1520784746 hasAuthorship W1520784746A5047328562 @default.
• W1520784746 hasAuthorship W1520784746A5066738891 @default.
• W1520784746 hasAuthorship W1520784746A5079788588 @default.
• W1520784746 hasAuthorship W1520784746A5083172675 @default.
• W1520784746 hasBestOaLocation W15207847461 @default.
• W1520784746 hasConcept C121608353 @default.
• W1520784746 hasConcept C126322002 @default.
• W1520784746 hasConcept C126838900 @default.
• W1520784746 hasConcept C141071460 @default.
• W1520784746 hasConcept C143409427 @default.
• W1520784746 hasConcept C143753070 @default.
• W1520784746 hasConcept C188816634 @default.
• W1520784746 hasConcept C2776235491 @default.
• W1520784746 hasConcept C2779466945 @default.
• W1520784746 hasConcept C2780192828 @default.
• W1520784746 hasConcept C2910468371 @default.
• W1520784746 hasConcept C71924100 @default.
• W1520784746 hasConceptScore W1520784746C121608353 @default.
• W1520784746 hasConceptScore W1520784746C126322002 @default.
• W1520784746 hasConceptScore W1520784746C126838900 @default.
• W1520784746 hasConceptScore W1520784746C141071460 @default.
• W1520784746 hasConceptScore W1520784746C143409427 @default.
• W1520784746 hasConceptScore W1520784746C143753070 @default.
• W1520784746 hasConceptScore W1520784746C188816634 @default.
• W1520784746 hasConceptScore W1520784746C2776235491 @default.
• W1520784746 hasConceptScore W1520784746C2779466945 @default.
• W1520784746 hasConceptScore W1520784746C2780192828 @default.
• W1520784746 hasConceptScore W1520784746C2910468371 @default.
• W1520784746 hasConceptScore W1520784746C71924100 @default.
• W1520784746 hasIssue "1" @default.
• W1520784746 hasLocation W15207847461 @default.
• W1520784746 hasLocation W15207847462 @default.
• W1520784746 hasOpenAccess W1520784746 @default.
• W1520784746 hasPrimaryLocation W15207847461 @default.
• W1520784746 hasRelatedWork W1623123377 @default.

• next